Does antiplatelet treatment with abciximab reduce cardiovascular events in patients with unstable coronary artery disease and elevated soluble CD40 ligand?
Elevated soluble CD40 ligand serves as a biomarker to identify patients with unstable coronary artery disease at high risk for cardiovascular events who may specifically benefit from abciximab therapy.
In patients with unstable coronary artery disease, elevation of soluble CD40 ligand levels indicated an increased risk of cardiovascular events. Elevation of soluble CD40 ligand identifies a subgroup of patients at high risk who are likely to benefit from antiplatelet treatment with abciximab.
Heeschen et al. (Wed,) studied this question.